Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study

The data on the adjuvant therapy of endometrial cancer (EC) are inconsistent. Recent studies of this topic such as PORTEC-3, GOG-258 and GOG-249 investigated the value of adjuvant radiotherapy, adjuvant chemotherapy and combined adjuvant chemoradiotherapy followed by chemotherapy in patients with en...

Descripción completa

Detalles Bibliográficos
Autores principales: Emons, Günther, Tempfer, Clemens, Battista, Marco Johannes, Mustea, Alexander, Vordermark, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195428/
https://www.ncbi.nlm.nih.gov/pubmed/30364421
http://dx.doi.org/10.1055/a-0658-1918
Descripción
Sumario:The data on the adjuvant therapy of endometrial cancer (EC) are inconsistent. Recent studies of this topic such as PORTEC-3, GOG-258 and GOG-249 investigated the value of adjuvant radiotherapy, adjuvant chemotherapy and combined adjuvant chemoradiotherapy followed by chemotherapy in patients with endometrial cancer and an increased risk of recurrence. With this statement, the Uterus Committee of the Gynaecological Oncology Working Group (AGO) wishes therefore to interpret the new data and discuss them against the background of the new S3 guideline “Diagnosis, treatment and follow-up of patients with endometrial cancer”.

Ejemplares similares